The European Medicines Agency has rejected a marketing authorisation request for the Alzheimer’s disease drug lecanemab, stating that […]

Doctors should “recommit to maintaining generalist skills” as they specialise so they can “respond to the inexorable rise […]

The Alzheimer’s disease treatment donanemab leads to a modest slowdown in cognitive decline in the early stages of […]

In my last column I discussed the lack of detail or meaningful change in the government’s Build Back […]

Around 40% of dementia cases worldwide could have potentially been delayed or prevented if 12 risk factors had […]